Meningitis Outbreak
Debate between Kirsty Blackman and Wes Streeting(3 days, 22 hours ago)
Commons ChamberRead Full debate Read Hansard Text Read Debate Ministerial Extracts
Wes Streeting
I thank my hon. Friend for sharing his awful experience, and for once again emphasising the importance of good public health information and advice, including for parents whose students will still be in Canterbury and who may therefore be particularly worried. UKHSA is now advising anyone who visited Club Chemistry on 5, 6 or 7 March to come forward for preventive antibiotic treatment as a precautionary measure; it can be collected from four sites. If they or people they know develop symptoms of meningitis or septicaemia, they should urgently seek medical help by going to the nearest accident and emergency department or dialling 999. If it is not an emergency but people are concerned, they can contact their GP or NHS 111.
Symptoms of meningitis and septicaemia can include a rash that does not fade when pressed with a glass; a sudden onset of high fever; a severe and worsening headache; a stiff neck; vomiting and diarrhoea; joint and muscle pain; a dislike of bright lights; very cold hands and feet; seizures; confusion or delirium; and extreme sleepiness or difficulty waking. I want to underscore that the general risk of transmission is low and that it takes place through close, direct and prolonged personal contact through things like kissing or sharing vapes and drinks. We need to get the balance right between promoting awareness—people thinking about their own situation and whether any of these factors apply to them—and not spreading unnecessary anxiety, because most people, including the overwhelming majority of students at the universities and people in Canterbury, will not be at risk.
Kirsty Blackman (Aberdeen North) (SNP)
Our thoughts are with everyone involved in this matter, particularly all those who are dealing with it, including medical professionals, university staff and UKHSA. I understand that the Secretary of State’s immediate priority today will be this specific outbreak. Dr Amirthalingam from UKHSA was on BBC Radio 4 this morning and suggested that the progression of the outbreak is atypical. Will the Secretary of State give a reassurance that the devolved health authorities will be given updates if there is another atypical progression anywhere else in these islands?
Wes Streeting
The hon. Member is absolutely right about the atypical nature of this outbreak. I can reassure her and the House that UKHSA is in regular contact with the devolved Administrations.
Puberty Suppressants Trial
Debate between Kirsty Blackman and Wes Streeting(3 months ago)
Commons ChamberRead Full debate Read Hansard Text Read Debate Ministerial Extracts
Urgent Questions are proposed each morning by backbench MPs, and up to two may be selected each day by the Speaker. Chosen Urgent Questions are announced 30 minutes before Parliament sits each day.
Each Urgent Question requires a Government Minister to give a response on the debate topic.
This information is provided by Parallel Parliament and does not comprise part of the offical record
Wes Streeting
I am grateful to my hon. Friend for his question. The reassurance that we can provide trans people in our country is that we are committed to making sure that they have access to the highest quality, evidence-based healthcare. That does not just apply in the case of children and young people; I also hope to report to the House before the Christmas recess the work undertaken in the learning disability mortality review into adult services. We are committed to making sure that we provide high-quality care to a particular vulnerable group of children and young people.
Kirsty Blackman (Aberdeen North) (SNP)
Although I disagreed with the permanent ban, it is to the Secretary of State’s credit that he has been very clear about all the competing issues that he is balancing to make his decisions, and I appreciate that. There are young people who are hoping to be part of the clinical trial and to receive puberty blockers, whether that will genuinely make a difference to their lives or they believe that it will make a difference to their lives. How will he ensure that appropriate support is given to those young people who do not get to be part of the trial, when they have been hoping that it will change their lives?
Wes Streeting
I am grateful to the hon. Member for the way that she asks her question, as a critic of some of the decisions that I have taken in this space. The reassurance that I can offer is that the study will look at the holistic care that this group of children and young people receives, and ensure that wider evidence-led therapeutic support, including mental health support, is available, so that regardless of whether a young person receives puberty blockers, they will certainly receive that wider range of support.